{"id":"https://openalex.org/W7225749704","doi":"https://doi.org/10.25251/vhsn4v56","title":"TibuSHIELD: A phase 2 randomized, double-blind, placebo-controlled study of Tibulizumab in adults with moderate-to-severe Hidradenitis Suppurativa","display_name":"TibuSHIELD: A phase 2 randomized, double-blind, placebo-controlled study of Tibulizumab in adults with moderate-to-severe Hidradenitis Suppurativa","publication_year":2026,"publication_date":"2026-11-10","ids":{"openalex":"https://openalex.org/W7225749704","doi":"https://doi.org/10.25251/vhsn4v56"},"language":"en","primary_location":{"id":"doi:10.25251/vhsn4v56","doi":"https://doi.org/10.25251/vhsn4v56","is_oa":true,"landing_page_url":"https://doi.org/10.25251/vhsn4v56","pdf_url":null,"source":{"id":"https://openalex.org/S4210210594","display_name":"SKIN The Journal of Cutaneous Medicine","issn_l":"2574-1624","issn":["2574-1624"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","poland-20"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"SKIN The Journal of Cutaneous Medicine","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"diamond","oa_url":"https://doi.org/10.25251/vhsn4v56","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5161365599","display_name":"Cathy Andorfer","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Cathy Andorfer","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5161388022","display_name":"Brandon Walsh","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Brandon Walsh","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059552004","display_name":"Vaishali R. Moulton","orcid":"https://orcid.org/0000-0002-6441-3264","observed_orcids":["https://orcid.org/0000-0002-6441-3264"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Vaishali R Moulton","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010567631","display_name":"Kate Lindsell","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kate Lindsell","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5161395780","display_name":"Catherine Crosby","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Catherine Crosby","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010730975","display_name":"Kiran Nistala","orcid":"https://orcid.org/0000-0002-5945-6104","observed_orcids":["https://orcid.org/0000-0002-5945-6104"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kiran Nistala","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5159137195","display_name":"Amit Garg","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Amit Garg","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008473117","display_name":"David M. Rosmarin","orcid":"https://orcid.org/0000-0003-2786-0708","observed_orcids":["https://orcid.org/0000-0003-2786-0708","https://orcid.org/0009-0008-8548-2198"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"David Rosmarin","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058475475","display_name":"Johann Eli Gudjonsson","orcid":"https://orcid.org/0000-0002-0080-0812","observed_orcids":["https://orcid.org/0000-0002-0080-0812"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Johann E Gudjonsson","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053721823","display_name":"Martina Lee Porter","orcid":"https://orcid.org/0000-0002-4738-4385","observed_orcids":["https://orcid.org/0000-0002-4738-4385"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Martina L Porter","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5059337854","display_name":"Alexa B. Kimball","orcid":"https://orcid.org/0000-0001-9405-0479","observed_orcids":["https://orcid.org/0000-0001-9405-0479"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Alexa B Kimball","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"10","issue":"6","first_page":"s829","last_page":"s829"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12731","display_name":"Hidradenitis Suppurativa and Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12731","display_name":"Hidradenitis Suppurativa and Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12328","display_name":"Autoimmune and Inflammatory Disorders","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T13328","display_name":"Osteomyelitis and Bone Disorders Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[],"concepts":[{"id":"https://openalex.org/C2776002364","wikidata":"https://www.wikidata.org/wiki/Q341999","display_name":"Hidradenitis suppurativa","level":3,"score":0.9243000149726868},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9158999919891357},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.8806999921798706},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5855000019073486},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.5458999872207642},{"id":"https://openalex.org/C2776173921","wikidata":"https://www.wikidata.org/wiki/Q25326609","display_name":"Dermatology Life Quality Index","level":3,"score":0.5259000062942505},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.5138000249862671},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.49380001425743103},{"id":"https://openalex.org/C2779951463","wikidata":"https://www.wikidata.org/wiki/Q7268788","display_name":"Quality of life (healthcare)","level":2,"score":0.4781000018119812},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.46959999203681946},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.38269999623298645},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.3540000021457672},{"id":"https://openalex.org/C527108885","wikidata":"https://www.wikidata.org/wiki/Q835153","display_name":"Physical examination","level":2,"score":0.3472000062465668},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.34049999713897705},{"id":"https://openalex.org/C30036603","wikidata":"https://www.wikidata.org/wiki/Q17125150","display_name":"Severity of illness","level":2,"score":0.3093000054359436},{"id":"https://openalex.org/C83849319","wikidata":"https://www.wikidata.org/wiki/Q7295720","display_name":"Rating scale","level":2,"score":0.2870999872684479},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.2858999967575073},{"id":"https://openalex.org/C1862650","wikidata":"https://www.wikidata.org/wiki/Q186005","display_name":"Physical therapy","level":1,"score":0.2802000045776367},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.2696000039577484},{"id":"https://openalex.org/C2777673923","wikidata":"https://www.wikidata.org/wiki/Q79928","display_name":"Acne","level":2,"score":0.25049999356269836}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.25251/vhsn4v56","doi":"https://doi.org/10.25251/vhsn4v56","is_oa":true,"landing_page_url":"https://doi.org/10.25251/vhsn4v56","pdf_url":null,"source":{"id":"https://openalex.org/S4210210594","display_name":"SKIN The Journal of Cutaneous Medicine","issn_l":"2574-1624","issn":["2574-1624"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","poland-20"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"SKIN The Journal of Cutaneous Medicine","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.25251/vhsn4v56","doi":"https://doi.org/10.25251/vhsn4v56","is_oa":true,"landing_page_url":"https://doi.org/10.25251/vhsn4v56","pdf_url":null,"source":{"id":"https://openalex.org/S4210210594","display_name":"SKIN The Journal of Cutaneous Medicine","issn_l":"2574-1624","issn":["2574-1624"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","poland-20"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"SKIN The Journal of Cutaneous Medicine","raw_type":"journal-article"},"sustainable_development_goals":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":8,"referenced_works":["https://openalex.org/W1825622469","https://openalex.org/W1982924102","https://openalex.org/W2503109448","https://openalex.org/W3042634019","https://openalex.org/W3194448077","https://openalex.org/W4296050169","https://openalex.org/W4310954687","https://openalex.org/W4404283674"],"related_works":[],"abstract_inverted_index":{"Background:":[0],"Hidradenitis":[1],"suppurativa":[2],"(HS)":[3],"is":[4,12,67,161,255,295,308,343],"a":[5,32,136,319],"chronic,":[6],"relapsing":[7],"inflammatory":[8,55,169],"skin":[9,209],"disease":[10],"that":[11],"characterized":[13],"by":[14,336],"recurrent":[15],"painful":[16],"nodules,":[17],"abscesses,":[18],"and":[19,30,46,60,75,90,110,168,184,187,205,219,231,284,334],"draining":[20,266],"tunnels.":[21],"Over":[22],"time,":[23],"these":[24],"lesions":[25,244],"can":[26],"progress":[27],"to":[28,86,126,270,281,286],"scarring":[29],"place":[31],"substantial":[33],"burden":[34],"on":[35,40],"patients,":[36],"with":[37,116,243,326],"significant":[38],"impacts":[39],"quality":[41],"of":[42,63,72,97,112,131,241,253,274,317,346],"life,":[43],"physical":[44],"health,":[45],"psychological":[47],"wellbeing.":[48],"Approved":[49],"HS":[50,180,200,242],"therapies":[51],"primarily":[52],"target":[53],"specific":[54],"pathways,":[56],"despite":[57],"the":[58,64,107,146,153,309,315],"complex":[59],"multifactorial":[61],"nature":[62],"disease.":[65],"Tibulizumab":[66],"an":[68,271,344],"investigational":[69],"dual":[70,320],"antagonist":[71,322],"interleukin17":[73],"(IL-17)":[74],"B-cell":[76,91],"activating":[77],"factor":[78],"(BAFF)":[79],"currently":[80],"being":[81],"studied":[82],"for":[83,152],"its":[84],"potential":[85],"simultaneously":[87],"inhibit":[88],"neutrophilic":[89],"drivers,":[92],"two":[93,128],"key":[94],"pathogenic":[95],"factors":[96],"HS.":[98,117,327],"Objective:":[99],"This":[100,293,330,341],"randomized,":[101],"double-blinded,":[102],"placebo-controlled":[103],"study":[104,294],"will":[105,149,221,298],"evaluate":[106],"efficacy,":[108],"safety,":[109],"tolerability":[111,220],"tibulizumab":[113,132],"in":[114,145,166,191,199,208,245,324],"adults":[115,325],"Methods:":[118],"247":[119],"participants":[120],"aged":[121],"18\u201370":[122],"were":[123],"randomized":[124,311],"1:1:1":[125],"receive":[127],"different":[129],"doses":[130],"or":[133,259,277,279],"placebo":[134],"during":[135],"double-blind":[137,147],"16-week":[138,154],"treatment":[139,144],"period.":[140],"Patients":[141],"who":[142],"complete":[143],"period":[148],"be":[150,222,299],"eligible":[151],"open":[155],"label":[156],"extension.":[157],"The":[158],"primary":[159],"endpoint":[160],"change":[162],"from":[163],"baseline":[164],"(CFB)":[165],"abscess":[167],"nodule":[170],"(AN)":[171],"count":[172,263],"at":[173,215,250,350],"week":[174,216],"16.":[175,217],"Key":[176,235],"secondary":[177],"endpoints":[178],"include":[179],"Clinical":[181],"Response":[182],"\u226550%":[183],"\u226575%":[185],"(HiSCR50":[186],"HiSCR75),":[188],"absolute":[189,197,206],"CFB":[190,198,207],"Dermatology":[192],"Life":[193],"Quality":[194],"Index":[195],"(DLQI),":[196],"Patient\u2019s":[201],"Global":[202],"Assessment":[203],"(HS-PtGA),":[204],"pain":[210],"numerical":[211],"rating":[212],"scale":[213],"(NRS)":[214],"Safety":[218],"investigated":[223],"through":[224],"treatment-emergent":[225],"adverse":[226],"events,":[227],"electrocardiogram,":[228],"vital":[229],"signs,":[230],"clinical":[232,312],"laboratory":[233],"assessments.":[234],"inclusion":[236],"criteria":[237],"includes":[238],"\u22656-months":[239],"history":[240],"\u22652":[246],"distinct":[247],"anatomical":[248],"areas,":[249],"least":[251],"one":[252],"which":[254],"Hurley":[256],"Stage":[257],"II":[258],"III,":[260],"total":[261],"AN":[262],"\u22655,":[264],"\u226420":[265],"tunnels,":[267],"inadequate":[268],"response":[269],"appropriate":[272],"course":[273],"oral":[275,282],"antibiotics":[276],"intolerance":[278],"contraindication":[280],"antibiotics,":[283],"agreement":[285],"use":[287],"highly":[288],"effective":[289],"contraception":[290],"methods.":[291],"Results:":[292],"ongoing.":[296],"Outcomes":[297],"reported":[300],"when":[301],"data":[302],"are":[303],"available.":[304],"Conclusion:":[305],"TibuSHIELD":[306],"(NCT06993610)":[307],"first":[310],"trial":[313],"investigating":[314],"effect":[316],"tibulizumab,":[318],"IL-17/BAFF":[321],"antibody,":[323],"Support":[328],"statement:":[329],"abstract":[331,342],"was":[332],"supported":[333],"funded":[335],"Zura":[337],"Bio.":[338],"Please":[339],"note:":[340],"encore":[345],"work":[347],"previously":[348],"presented":[349],"SHSA":[351],"2025.":[352]},"counts_by_year":[],"updated_date":"2026-11-11T12:16:26.678958","created_date":"2026-11-11T00:00:00"}